Kidney cancer trial: new combo vs. cabozantinib alone
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug (casdatifan) combined with cabozantinib for advanced clear cell kidney cancer, comparing it to cabozantinib alone. It's for people who haven't taken these specific medicines before and are still in fairly good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your kidney cancer must be advanced (cannot be removed by surgery) and include a type called 'clear cell'.
- You should be able to take care of most daily tasks (Karnofsky score of 80% or higher).
- You cannot have already taken certain medicines (cabozantinib or a HIF-2α inhibitor).
- Your blood pressure must be well-controlled (under 150/90).
- You cannot have had another active cancer in the last year, except for minor ones that are cured.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This study tests two new drugs, zanzalintinib and MO-03, for people whose kidney cancer has grown after treatment with immunotherapy and cabozantinib. The goal is to see if combining these drugs helps control the cancer.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests an experimental drug (HC-7366) combined with an approved targeted therapy (belzutifan) for people with advanced kidney cancer. It aims to see if the combination is safe and works better than either drug alone.
This study tests the drug cabozantinib in people with kidney cancer who are also on dialysis. It aims to see if the drug is safe and works for this group.
This study tests a new combination of medications (casdatifan and zimberelimab) given before surgery to remove kidney tumors in people with clear cell renal cell carcinoma (ccRCC). The goal is to see if this approach can help shrink the tumor or improve outcomes.
Hear when a new Metastatic Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.